Венозные тромбозы и тромбоэмболии у онкологических больных

Автор: Дундуа Д.П., Кедрова А.Г., Олейникова И.Н., Плохова Е.В., Хабазов Р.Р.

Журнал: Клиническая практика @clinpractice

Статья в выпуске: 3 т.15, 2024 года.

Бесплатный доступ

Тромбоз глубоких вен и тромбоэмболия лёгочной артерии - наиболее часто встречающиеся сердечно-сосудистые осложнения онкологического заболевания, которые могут возникать на любой стадии онкологического процесса. Эти жизнеугрожающие осложнения занимают лидирующие позиции в структуре смертности у онкобольных, уступая место только самому онкозаболеванию. Необходимо заметить, что пациенты с онкоассоциированными тромбозами - это наиболее тяжёлая группа больных, у которых возникновение тромбозов и тромбоэмболий может не только отсрочить жизненно важное лечение основного заболевания, но и полностью исключить его ввиду невозможности проведения адекватной терапии. Это важная социальная и экономическая задача, учитывая затраты здравоохранения на лечение самого заболевания и сопутствующих осложнений. Таким образом, остро стоит вопрос не только самого лечения, но и профилактики онкоассоциированных тромбозов и тромбоэмболий. В настоящее время в связи с распространением данных осложнений лечение и профилактика претерпевают большие изменения. Традиционно использовался варфарин, на смену которому пришёл низкомолекулярный гепарин. На данный момент всё чаще используются пероральные антикоагулянты. Анализ специальной научной литературы позволил оценить новые принципы лечения онкоассоциированных тромбозов и тромбоэмболий в зависимости от локализации процесса, его стадии, тяжести состояния пациента, а также определить факторы риска онкоассоциированных тромбозов, целесообразность и возможные методы их профилактики в разных группах пациентов.

Еще

Тромбоз глубоких вен, тромбоэмболия лёгочной артерии, онкоассоциированные тромбозы

Короткий адрес: https://sciup.org/143183415

IDR: 143183415 | DOI: 10.17816/clinpract634775

Список литературы Венозные тромбозы и тромбоэмболии у онкологических больных

Khorana AA. Malignancy, thrombosis and Trousseau: The case for an eponym. J Thromb Haemost. 2003;1(12):2463–2465. doi: 10.1111/j.1538-7836.2003.00501.x
Donnellan E, Khorana AA. Cancer and venous thromboembolic disease: A review. Oncologist. 2017;22(2):199–207. doi: 10.1634/theoncologist.2016-0214
Cohoon KP, Ransom JE, Leibson CL, et al. Direct medical costs attributable to cancer-associated venous thromboembolism: A population-based longitudinal study. Am J Med. 2016; 129(9):1000.e15–25. doi: 10.1016/j.amjmed.2016.02.030
Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3): 632–634. doi: 10.1111/j.1538-7836.2007.02374.x
Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484–3488. doi: 10.1182/blood-2002-01-0108
Mukai M, Oka T. Mechanism and management of cancerassociated thrombosis. J Cardiol. 2018;72(2):89–93. doi: 10.1016/j.jjcc.2018.02.011
Patel HK, Khorana AA. Anticoagulation in cancer patients: A summary of pitfalls to avoid. Curr Oncol Rep. 2019;21(2):18. doi: 10.1007/s11912-019-0767-5
Walker AJ, Card TR, West J, et al. Incidence of venous thromboembolism in patients with cancer: A cohort study using linked United Kingdom databases. Eur J Cancer. 2013; 49(6):1404–1413. doi: 10.1016/j.ejca.2012.10.021
Eichinger S. Cancer associated thrombosis: risk factors and outcomes. Thromb Res. 2016;140(Suppl. 1):S12–17. doi: 10.1016/S0049-3848(16)30092-5
Navi BB, Reiner AS, Kamel H, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol. 2017;70(8):926–938. doi: 10.1016/j.jacc.2017.06.047
Donadini MP, Ageno W. Unusual site thrombosis. Semin Hematol. 2011;48(4):264–270. doi: 10.1053/j.seminhematol.2011.08.005
Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496–520. doi: 10.1200/JCO.19.01461
Farge D, Frere C, Connors JM, et al. 2019 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20(10):e566–581. doi: 10.1016/S1470-2045(19)30336-5
Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22(Suppl. 6):vi85–92. doi: 10.1093/annonc/mdr392
Streiff MB, Holmstrom B, Angelini D, et al. Cancer-associated venous thromboembolic disease, Version 1.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(10):1181–1201. doi: 10.6004/jnccn.2021.0047
Васюк Ю.А., Гендлин Г.Е. Согласованное мнение российских экспертов по профилактике, диагностике и лечению сердечно-сосудистой токсичности противоопухолевой терапии // Российский кардиологический журнал. 2021. Т. 26, № 9. С. 152–233. [Vasyuk YuA, Gendlin GE, Emelina EI, et al. Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russ J Cardiol. 2021;26(9):152–233]. EDN: GZXWWW doi: 10.15829/1560-4071-2021-4703
Lowe GD. Common risk factors for both arterial and venous thrombosis. Br J Haematol. 2008;140(5):488–495. doi: 10.1111/j.1365-2141.2007.06973.x
Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009;27(29):4839–4847. doi: 10.1200/JCO.2009.22.3271
Gervaso L, Dave H, Khorana A.A. Venous and arterial thromboembolism in patients with cancer. JACC CardioOncology. 2021;3(2):173–190. doi: 10.1016/j.jaccao.2021.03.001
Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339–2346. doi: 10.1002/cncr.23062
Vergati M, Della-Morte D, Ferroni P, et al. Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer. Rejuvenation Res. 2013;16(3):224–231. doi: 10.1089/rej.2013.1409
Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet. 2001;109(4):369–384. doi: 10.1007/s004390100593
Connolly GC, Khorana AA. Emerging risk stratification approaches to cancer-associated thrombosis: Risk factors, biomarkers and a risk score. Thromb Res. 2010;125(Suppl. 2): S1–7. doi: 10.1016/S0049-3848(10)00227-6
Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–722. doi: 10.1001/jama.293.6.715
Dickmann B, Ahlbrecht J, Ay C, et al. Regional lymph node metastases are a strong risk factor for venous thromboembolism: Results from the Vienna Cancer and Thrombosis Study. Haematologica. 2013;98(8):1309–1314. doi: 10.3324/haematol.2012.073338
Connolly GC, Francis CW. Cancer-associated thrombosis. Hematology Am Soc Hematol Educ Program. 2013;2013: 684–691. doi: 10.1182/asheducation-2013.1.684
Li W, Garcia D, Cornell RF, et al. Cardiovascular and thrombotic complications of novel multiple myeloma therapies: A review. JAMA Oncol. 2017;3(7):980–988. doi: 10.1001/jamaoncol.2016.3350
Kristinsson SY, Pfeiffer RM, Björkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: A population-based study. Blood. 2010;115(24):4991–4998. doi: 10.1182/blood-2009-11-252072
Roopkumar J, Poudel SK, Gervaso L, et al. Risk of thromboembolism in patients with ALK and EGFR-mutant lung cancer: A cohort study. J Thromb Haemost. 2021;19(3): 822–829. doi: 10.1111/jth.15215
Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: The @RISTOS project. Ann Surg. 2006;243(1):89–95. doi: 10.1097/01.sla.0000193959.44677.48
Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013;119(3):648–655. doi: 10.1002/cncr.27772
Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46. doi: 10.1056/NEJMoa073149
Cavo M, Zamagni E, Cellini C, et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomidedexamethasone therapy. Blood. 2002;100(6):2272–2273. doi: 10.1182/blood-2002-06-1674
Tamborini Permunian E, Gervaso L, Gerdes V, et al. Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: A systematic review. Intern Emerg Med. 2018;13(5): 775–790. doi: 10.1007/s11739-018-1828-8
Schutz FA, Je Y, Azzi GR, et al. Bevacizumab increases the risk of arterial ischemia: A large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol. 2011;22(6): 1404–1412. doi: 10.1093/annonc/mdq587
Choueiri TK, Schutz FA, Je Y, et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010;28(13): 2280–2285. doi: 10.1200/JCO.2009.27.2757
Roopkumar J, Swaidani S, Kim AS, et al. Increased incidence of venous thromboembolism with cancer immunotherapy. Med. 2012;2(4):423–434. doi: 10.1016/j.medj.2021.02.002
Khorana AA, Francis CW, Blumberg N, et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008;168(21):2377–2381. doi: 10.1001/archinte.168.21.2377
Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy associated venous thromboembolism in a prospective observational study. Cancer. 2005;104(12): 2822–2829. doi: 10.1002/cncr.21496
Khorana AA. Cancer-associated thrombosis: Updates and controversies. Hematology Am Soc Hematol Educ Program. 2012;2012:626–630. doi: 10.1182/asheducation-2012.1.626
Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1 þ 2 predict venous thromboembolism in patients with cancer: Results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009;27(25):4124–4129. doi: 10.1200/JCO.2008.21.7752
Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24): 5377–5382. doi: 10.1182/blood-2010-02-270116
Van Es N, di Nisio M, Cesarman G, et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: A prospective cohort study. Haematologica. 2017;102(9):1494–1501. doi: 10.3324/haematol.2017.169060
Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy associated thrombosis. Blood. 2008;111(10):4902–4907. doi: 10.1182/blood-2007-10-116327
Mulder FI, Candeloro M, Kamphuisen PW, et al. The Khorana score for prediction of venous thromboembolism in cancer patients: A systematic review and meta-analysis. Haematologica. 2019;104(6):1277–1287. doi: 10.3324/haematol.2018.209114
Khorana AA, Francis CW, Kuderer NM, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thromb Res. 2017;151:89–95. doi: 10.1016/j.thromres.2017.01.009
Kunapareddy G, Switzer B, Jain P, et al. Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology setting. Res Pract Thromb Haemost. 2019;3(2):226–233. doi: 10.1002/rth2.12176
White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003;90(3):446–455. doi: 10.1160/TH03-03-0152
Fagarasanu A, Alotaibi GS, Hrimiuc R, et al. Role of extended thromboprophylaxis after abdominal and pelvic surgery in cancer patients: A systematic review and meta-analysis. Ann Surg Oncol. 2016;23(5):1422–1430. doi: 10.1245/s10434-016-5127-1
Burleigh E, Wang C, Foster D, et al. Thromboprophylaxis in medically ill patients at risk for venous thromboembolism. Am J Health Syst Pharm. 2006;63(20, Suppl. 6):S23–29. doi: 10.2146/ajhp060390
Zwicker JI, Roopkumar J, Puligandla M, et al. Doseadjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: A randomized, double-blinded multicenter phase 2 trial. Blood Adv. 2020;4(10):2254–2260. doi: 10.1182/bloodadvances.2020001804
Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: The Padua Prediction Score. J Thromb Haemost. 2010;8(11):2450–2457. doi: 10.1111/j.1538-7836.2010.04044.x
Di Nisio M, Carrier M, Lyman GH, Khorana AA. Subcommittee on Haemostasis and Malignancy. Prevention of venous thromboembolism in hospitalized medical cancer patients: Guidance from the SSC of the ISTH. J Thromb Haemost. 2014;12(10):1746–1749. doi: 10.1111/jth.12683
Patell R, Rybicki L, McCrae KR, Khorana AA. Predicting risk of venous thromboembolism in hospitalized cancer patients: Utility of a risk assessment tool. Am J Hematol. 2017;92(6): 501–507. doi: 10.1002/ajh.24700
Hull RD, Schellong SM, Tapson VF, et al. Extendedduration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: A randomized trial. Ann Intern Med. 2010;153(1):8–18. doi: 10.7326/0003-4819-153-1-201007060-00004
Spencer FA, Lessard D, Emery C, et al. Venous thromboembolism
in the outpatient setting. Arch Intern Med. 2007;167(14): 1471–1475. doi: 10.1001/archinte.167.14.1471
Lyman GH, Eckert L, Wang Y, et al. Venous thromboembolism risk in patients with cancer receiving chemotherapy: A realworld analysis. Oncologist. 2013;18(12):1321–1329. doi: 10.1634/theoncologist.2013-0226
Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994;343(8902):886–889. doi: 10.1016/s0140-6736(94)90008-6
Verso M, Agnelli G, Barni S, et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: The PROTECHT score. Intern Emerg Med. 2012;7(3):291–292. doi: 10.1007/s11739-012-0784-y
Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601–609. doi: 10.1056/NEJMoa1108898
Di Nisio M, Porreca E, Candeloro M, et al. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2016;12(12):CD008500. doi: 10.1002/14651858.CD008500.pub5
Riess H, Pelzer U, Hilbig A, et al. Rationale and design of PROSPECT-CONKO 004: A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer. 2008;8:361. doi: 10.1186/1471-2407-8-361
Maraveyas A, Waters J, Roy R, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer. 2012;48(9):1283–1292. doi: 10.1016/j.ejca.2011.10.017
Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–153. doi: 10.1056/NEJMoa025313
Lee AY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial. JAMA. 2015;314(7):677–686. doi: 10.1001/jama.2015.9243
Kahale LA, Hakoum MB, Tsolakian IG, et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018;6(6):CD006650. doi: 10.1002/14651858.CD006650.pub5
Khorana AA, Yannicelli D, McCrae KR, et al. Evaluation of US prescription patterns: are treatment guidelines for cancerassociated venous thromboembolism being followed? Thromb Res. 2016;145:51–53. doi: 10.1016/j.thromres.2016.07.013
Van der Hulle T, den Exter PL, van den Hoven P, et al. Cohort study on the management of cancer-associated venous thromboembolism aimed at the safety of stopping anticoagulant therapy in patients cured of cancer. Chest. 2016;149(5): 1245–1251. doi: 10.1016/j.chest.2015.10.069
Agnelli G, Becattini C, Meyer G., et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599–1607. doi: 10.1056/NEJMoa1915103
McBane R, Wysokinski WE, Le Rademacher JG, et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism: The ADAM VTE Trial. J Thromb Haemost. 2020;18(2):411–442. doi: 10.1111/jth.14662
Francis CW, Kessler CM, Goldhaber SZ, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: The DALTECAN Study. J Thromb Haemost. 2015;13(6):1028–1035. doi: 10.1111/jth.12923
Jara-Palomares L, Solier-Lopez A, EliasHernandez T, et al. Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study. Thromb Res. 2017;157:90–96. doi: 10.1016/j.thromres.2017.07.004
Singh R, Sousou T, Mohile S, Khorana AA. High rates of symptomatic and incidental thromboembolic events in gastrointestinal cancer patients. J Thromb Haemost. 2010;8(8):1879–1881. doi: 10.1111/j.1538-7836.2010.03929.x
Chaturvedi S, Sidana S, Elson P, et al. Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer. PLoS One. 2014;9(8):e94048. doi: 10.1371/journal.pone.0094048
Di Nisio M, Carrier M. Incidental venous thromboembolism: Is anticoagulation indicated? Hematology Am Soc Hematol Educ Program. 2017;2017(1):121–127. doi: 10.1182/asheducation-2017.1.121
Galanaud JP, Sevestre MA, Pernod G, et al. Long-term outcomes of cancer-related isolated distal deep vein thrombosis: The OPTIMEV study. J Thromb Haemost. 2017;15(5):907–916. doi: 10.1111/jth.13664
Dentali F, Pegoraro S, Barco S, et al. Clinical course of isolated distal deep vein thrombosis in patients with active cancer: A multicenter cohort study. J Thromb Haemost. 2017;15(9): 1757–1763. doi: 10.1111/jth.13761
Carrier M, Khorana AA, Zwicker J, et al.; Subcommittee on Haemostasis and malignancy for the SSC of the ISTH. Management of challenging cases of patients with cancer associated thrombosis including recurrent thrombosis and bleeding: Guidance from the SSC of the ISTH. J Thromb Haemost. 2013;11(9):1760–1765. doi: 10.1111/jth.12338
Kopolovic I, Lee AY, Wu C. Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: A retrospective cohort study. Ann Hematol. 2015;94(2):329–336. doi: 10.1007/s00277-014-2198-6
Barco S, Corti M, Trinchero A, et al. Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolism. J Thromb Haemost. 2017;15(7):1436–1442. doi: 10.1111/jth.13713
Samuelson Bannow BT, Lee A, Khorana AA, et al. Management of cancer-associated thrombosis in patients with thrombocytopenia: Guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(6):1246–1249. doi: 10.1111/jth.14015
Samuelson Bannow BR, Lee AY, Khorana AA, et al. Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. Res Pract Thromb Haemost. 2018;2(4):664–669. doi: 10.1002/rth2.12111
Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–352. doi: 10.1016/j.chest.2015.11.026
Mismetti P, Laporte S, Pellerin O, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: A randomized clinical trial. JAMA. 2015;313(16):1627–1635. doi: 10.1001/jama.2015.3780
Brandes AA, Scelzi E, Salmistraro G, et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: A prospective study. Eur J Cancer. 1997;33(10):1592–1596. doi: 10.1016/s0959-8049(97)00167-6
Srivastava G, Rana V, Wallace S, et al. Risk of intracranial hemorrhage and cerebrovascular accidents in non-small cell lung cancer brain metastasis patients. J Thorac Oncol. 2009;4(3):333–337. doi: 10.1097/JTO.0b013e318194fad4
Donato J, Campigotto F, Uhlmann EJ, et al. Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: A matched cohort study. Blood. 2015;126(4):494–499. doi: 10.1182/blood-2015-02-626788
Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients. J Thromb Haemost. 2005;3(4):692–694. doi: 10.1111/j.1538-7836.2005.01204.x

Еще

Статья обзорная